NYSEAMERICAN:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis → Do This Before July 30 2024 To Claim Trump’s Gift (From Wealthpin Pro) (Ad) Free ATNM Stock Alerts $8.15 +0.04 (+0.49%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$8.06▼$8.4350-Day Range N/A52-Week Range$4.00▼$10.24Volume198,897 shsAverage Volume319,433 shsMarket Capitalization$242.71 millionP/E RatioN/ADividend YieldN/APrice Target$25.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Actinium Pharmaceuticals alerts: Email Address Actinium Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside214.1% Upside$25.60 Price TargetShort InterestHealthy7.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.48) to $0.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.68 out of 5 stars 3.5 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Actinium Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.02% of the outstanding shares of Actinium Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverActinium Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Actinium Pharmaceuticals has recently decreased by 10.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNM. Previous Next 2.6 News and Social Media Coverage News SentimentActinium Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Actinium Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 34 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.MarketBeat Follows7 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.Read more about Actinium Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.48) to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 5.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.Read More ATNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNM Stock News HeadlinesMay 29 at 5:54 PM | finance.yahoo.comAEG Honors API Desi Heritage Month With a Diverse Range of Engagement and Educational Opportunities for EmployeesMay 29 at 5:54 PM | oilprice.comAPI Reports Significant Draw in Crude Oil InventoriesMay 29 at 10:11 AM | finance.yahoo.comVoPay Launches TXB Solution to Help Banks and Credit Unions Implement API-First Transaction Banking and Cash ManagementMay 29 at 8:14 AM | finance.yahoo.comEurope's Leading Embedded Finance Platform, Solaris SE Taps Salt Security for API ProtectionMay 24, 2024 | markets.businessinsider.comActinium Pharmaceuticals’ Strong Outlook on Iomab-ACT and Pipeline Advancements Prompt Buy RatingMay 22, 2024 | markets.businessinsider.comBuy Rating for Actinium Pharmaceuticals Based on Strategic Market Positioning and Promising Clinical Developments of Iomab-ACTMay 22, 2024 | americanbankingnews.comActinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterated by HC WainwrightMay 21, 2024 | markets.businessinsider.comIomab-ACT’s Market Potential and Clinical Promise Drive Buy Rating for Actinium PharmaceuticalsMay 21, 2024 | americanbankingnews.comActinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Given Average Rating of "Buy" by AnalystsMay 15, 2024 | prnewswire.comActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market OpportunityMay 14, 2024 | markets.businessinsider.comActinium : Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML PatientsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Actinium Pharmaceuticals’ Clinical Triumphs and Strategic Market PositioningMay 14, 2024 | prnewswire.comActinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA TrialMay 14, 2024 | msn.comStephens & Co. Initiates Coverage of Actinium Pharmaceuticals (ATNM) with Overweight RecommendationMay 14, 2024 | investorplace.com3 Cheap Biotech Stocks to Buy Now: May 2024May 13, 2024 | prnewswire.comActinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingMay 12, 2024 | seekingalpha.comA Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted RadiotherapiesMay 7, 2024 | prnewswire.comActinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas SouthwesternMay 2, 2024 | msn.comRadiopharma stocks higher as sector welcomes the latest M&A dealMay 1, 2024 | tmcnet.comPostman Announces Winners of Inaugural Postman API Network AwardsMay 1, 2024 | finance.yahoo.comPostman Supercharges AI Development with New API Enhancements at POST/CON 2024May 1, 2024 | tmcnet.comSandbox Banking chosen to be API Management and Integration Platform as a Service (iPaaS) provider for new COCC ConnectSuite platformMay 1, 2024 | yahoo.comCitigroup's VC arm invests in API security startup TraceableApril 30, 2024 | msn.comOil inventories in surprise inventory build last week: APIApril 30, 2024 | finance.yahoo.comAI, Machine Learning Are the New Battleground for API Exploits, According to New Wallarm ReportSee More Headlines Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/26/2024Today5/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone(646) 677-3870FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$25.60 High Stock Price Target$50.00 Low Stock Price Target$11.60 Potential Upside/Downside+217.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,820,000.00 Net MarginsN/A Pretax Margin-57,346.92% Return on Equity-105.04% Return on Assets-51.93% Debt Debt-to-Equity RatioN/A Current Ratio10.59 Quick Ratio10.59 Sales & Book Value Annual Sales$80,000.00 Price / Sales3,004.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book5.49Miscellaneous Outstanding Shares29,780,000Free Float28,592,000Market Cap$240.32 million OptionableNot Optionable Beta0.08 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Sandesh C. Seth M.B.A. (Age 60)M.S., Chairman & CEO Comp: $1.15MMr. Steven O'Loughlin BS (Age 38)CFO & Corporate Secretary Comp: $585kDr. Paul Diamond Esq.Ph.D., Vice President of Patent & Legal CounselDr. David GouldSenior Vice President of Corporate Development & Corporate AffairsDr. Bernie Cunningham P.M.P.Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project ManagementDr. Qing LiangVP & Head of Radiation SciencesDr. Avinash Desai M.D.Chief Medical OfficerMs. Jenny HsiehChief Strategy OfficerMs. Sunitha LakshminarayananSenior VP, Head of CMC & Product DevelopmentMs. Elaina HaeuberVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVABicycle TherapeuticsNASDAQ:BCYCVerona PharmaNASDAQ:VRNALiquidiaNASDAQ:LQDAOPKO HealthNASDAQ:OPKView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 62,459 shares on 5/20/2024Ownership: 0.275%Vanguard Group Inc.Bought 82,113 shares on 5/10/2024Ownership: 4.857%Simplex Trading LLCBought 13,600 shares on 4/25/2024Ownership: 0.000%Sanders Morris Harris LLCBought 10,000 shares on 4/11/2024Ownership: 0.034%View All Institutional Transactions ATNM Stock Analysis - Frequently Asked Questions Should I buy or sell Actinium Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATNM shares. View ATNM analyst ratings or view top-rated stocks. What is Actinium Pharmaceuticals' stock price target for 2024? 6 brokers have issued 1-year price objectives for Actinium Pharmaceuticals' stock. Their ATNM share price targets range from $11.60 to $50.00. On average, they predict the company's stock price to reach $25.60 in the next twelve months. This suggests a possible upside of 214.1% from the stock's current price. View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts. How have ATNM shares performed in 2024? Actinium Pharmaceuticals' stock was trading at $5.24 at the start of the year. Since then, ATNM shares have increased by 55.5% and is now trading at $8.15. View the best growth stocks for 2024 here. Are investors shorting Actinium Pharmaceuticals? Actinium Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,090,000 shares, a decrease of 10.3% from the April 30th total of 2,330,000 shares. Based on an average daily volume of 404,700 shares, the days-to-cover ratio is presently 5.2 days. View Actinium Pharmaceuticals' Short Interest. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its quarterly earnings results on Friday, April, 26th. The biotechnology company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.11. When did Actinium Pharmaceuticals' stock split? Shares of Actinium Pharmaceuticals reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO). Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.86%), Virtu Financial LLC (0.28%), Simplex Trading LLC (0.00%), Sanders Morris Harris LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:ATNM) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaElon Musk’s Final Masterpiece: “X-9840”Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.